The efficacy of the ultraviolet <scp>C</scp> pathogen inactivation system in the reduction of <i><scp>B</scp>abesia divergens</i> in pooled buffy coat platelets

Castro, Emma; González, Luís Miguel; Rubio, José Miguel; Ramiro, Raquel; Gironès, Núria; Montero, Estrella

doi:10.1111/trf.12598

Cited by 26 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UVC treatment inactivates a wide spectrum of bacteria, parasites, viruses, and contaminating leukocytes [4,6,27,28,29,30]. Although HIV, and possibly other retroviruses, appear less sensitive to inactivation by UVC light, this is somewhat compensated by the fact that the residual risk of HIV transmission in Australia is exceptionally small (modelled to be less than 1 in 7 million) [31].…”

Section: Discussionmentioning

confidence: 99%

In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation

Johnson

Hyland

Tan

et al. 2015

Transfus Med Hemother

View full text Add to dashboard Cite

Background: The THERAFLEX UV-Platelets system uses shortwave ultraviolet C light (UVC, 254 nm) to inactivate pathogens in platelet components. Plasma carryover influences pathogen inactivation and platelet quality following treatment. The plasma carryover in the standard platelets produced by our institution are below the intended specification (<30%). Methods: A pool and split study was carried out comparing untreated and UVC-treated platelets with <30% plasma carryover (n = 10 pairs). This data was compared to components that met specifications (>30% plasma). The platelets were tested over storage for in vitro quality. Results: Platelet metabolism was accelerated following UVC treatment, as demonstrated by increased glucose consumption and lactate production. UVC treatment caused increased externalization of phosphatidylserine on platelets and microparticles, activation of the GPIIb/IIIa receptor (PAC-1 binding), and reduced hypotonic shock response. Platelet function, as measured with thrombelastogram, was not affected by UVC treatment. Components with <30% plasma were similar to those meeting specification with the exception of enhanced glycolytic metabolism. Conclusion: This in vitro analysis demonstrates that treatment of platelets with <30% plasma carryover with the THERAFLEX UV-Platelets system affects some aspects of platelet metabolism and activation, although in vitro platelet function was not negatively impacted. This study also provides evidence that the treatment specifications of plasma carryover could be extended to below 30%.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation

Johnson

Hyland

Tan

et al. 2015

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Pathogen inactivation efficacy for platelet concentrates[24,89,60,62,63,[70][71][72][73][74][75][76][77][78][79] …”

mentioning

confidence: 99%

Pathogen Inactivation Technologies for Cellular Blood Components: an Update

Schlenke¹

2014

Transfus Med Hemother

112

114

View full text Add to dashboard Cite

Nowadays patients receiving blood components are exposed to much less transfusion-transmitted infectious diseases than three decades before when among others HIV was identified as causative agent for the acquired immunodeficiency syndrome and the transmission by blood or coagulation factors became evident. Since that time the implementation of measures for risk prevention and safety precaution was socially and politically accepted. Currently emerging pathogens like arboviruses and the well-known bacterial contamination of platelet concentrates still remain major concerns of blood safety with important clinical consequences, but very rarely with fatal outcome for the blood recipient. In contrast to the well-established pathogen inactivation strategies for fresh frozen plasma using the solvent-detergent procedure or methylene blue and visible light, the bench-to-bedside translation of novel pathogen inactivation technologies for cell-containing blood components such as platelets and red blood cells are still underway. This review summarizes the pharmacological/toxicological assessment and the inactivation efficacy against viruses, bacteria, and protozoa of each of the currently available pathogen inactivation technologies and highlights the impact of the results obtained from several randomized clinical trials and hemovigilance data. Until now in some European countries pathogen inactivation technologies are in in routine use for single-donor plasma and platelets. The invention and adaption of pathogen inactivation technologies for red blood cell units and whole blood donations suggest the universal applicability of these technologies and foster a paradigm shift in the manufacturing of safe blood.

show abstract

“…This is important for blood centers that have ineligible donors due to testing performed under IND and will remain relevant as testing expands. Fourth, the Babesia Report does not consider the role of pathogen inactivation to replace donor testing despite data that show its potential for mitigating TTB . These factors suggest the need for clear criteria for including and excluding relevant literature as well as the ability to integrate and apply new data in the RBDM process.…”

Section: Babesia Rbdm Reportmentioning

confidence: 99%

Risk‐based decision making: a good start to aiding US blood policy decisions?

Shaz

2018

Transfusion

View full text Add to dashboard Cite

The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets

Abstract: Since B. divergens can survive in PLT concentrates and given the performance of UVC, this system could be considered as an alternative to prevent B. divergens and other Babesia species from being transmitted through PLT transfusions.

Cited by 26 publications

References 34 publications

In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation

In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation

Pathogen Inactivation Technologies for Cellular Blood Components: an Update

Risk‐based decision making: a good start to aiding US blood policy decisions?

Contact Info

Product

Resources

About